HK1200168A1 - Meldrum s acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors hno - Google Patents

Meldrum s acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors hno

Info

Publication number
HK1200168A1
HK1200168A1 HK15100597.0A HK15100597A HK1200168A1 HK 1200168 A1 HK1200168 A1 HK 1200168A1 HK 15100597 A HK15100597 A HK 15100597A HK 1200168 A1 HK1200168 A1 HK 1200168A1
Authority
HK
Hong Kong
Prior art keywords
hno
acid
meldrum
hydroxylamine
donors
Prior art date
Application number
HK15100597.0A
Other languages
English (en)
Chinese (zh)
Inventor
Daryl A Guthrie
John P Toscano
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of HK1200168A1 publication Critical patent/HK1200168A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15100597.0A 2011-10-17 2015-01-19 Meldrum s acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors hno HK1200168A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161548036P 2011-10-17 2011-10-17
PCT/US2012/060425 WO2013059194A1 (en) 2011-10-17 2012-10-16 Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors

Publications (1)

Publication Number Publication Date
HK1200168A1 true HK1200168A1 (en) 2015-07-31

Family

ID=47143299

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100597.0A HK1200168A1 (en) 2011-10-17 2015-01-19 Meldrum s acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors hno

Country Status (13)

Country Link
US (3) US9181213B2 (xx)
EP (1) EP2776402B1 (xx)
JP (1) JP6177246B2 (xx)
KR (1) KR102061537B1 (xx)
CN (2) CN104053647B (xx)
AU (2) AU2013201929B2 (xx)
BR (1) BR112014009282B1 (xx)
CA (1) CA2852914C (xx)
HK (1) HK1200168A1 (xx)
IL (1) IL232101A (xx)
MX (1) MX363306B (xx)
SG (1) SG11201401587QA (xx)
WO (1) WO2013059194A1 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6177246B2 (ja) 2011-10-17 2017-08-09 ザ・ジョンズ・ホプキンス・ユニバーシティ ヒドロキシルアミンで置換された、ｈｎｏ供与体としてのメルドラム酸、バルビツール酸、及びピラゾロンの誘導体
US10245249B2 (en) 2013-01-18 2019-04-02 Cardioxyl Pharmaceuticals, Inc. Pharmaceutical compositions comprising nitroxyl donors
WO2015109210A1 (en) 2014-01-17 2015-07-23 Cardioxyl Pharmaceuticals, Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9682938B2 (en) 2014-05-27 2017-06-20 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US9464061B2 (en) * 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
EP3148983A1 (en) 2014-05-27 2017-04-05 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
CN107922371B (zh) * 2015-06-26 2022-04-19 约翰斯霍普金斯大学 作为有效的hno供体的具有碳基离去基团的n-取代的异羟肟酸及其用途
US10723704B2 (en) 2015-10-19 2020-07-28 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US10730828B2 (en) 2015-10-19 2020-08-04 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as nitroxyl donors
CN110139854A (zh) * 2016-07-28 2019-08-16 约翰斯霍普金斯大学 O-取代异羟肟酸
BR112019013702A2 (pt) 2017-01-03 2020-03-03 Cardioxyl Pharmaceuticals, Inc. Método de administração de compostos doadores de nitroxila
MA54133B1 (fr) 2018-03-08 2022-01-31 Incyte Corp Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US11912647B2 (en) 2020-05-22 2024-02-27 University Of Georgia Research Foundation, Inc. Diversity-oriented synthesis of N,N,O-trisubstituted hydroxylamines from alcohols and amines by N—O bond formation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
CA2306914A1 (en) 1997-10-24 1999-05-06 Shionogi & Co., Ltd. Antirheumatic
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
CN1163223C (zh) 1998-07-28 2004-08-25 田边制药株式会社 肠内目标部位释放型制剂
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
WO2005074598A2 (en) 2004-01-30 2005-08-18 Johns Hopkins University Nitroxyl progenitor compounds and methods of use
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
EP1909779A1 (en) 2005-06-23 2008-04-16 Johns Hopkins University Thiol-sensitive positive inotropes
SI2586435T1 (sl) * 2006-03-17 2016-12-30 The Johns Hopkins University Derivati N-hidroksilsulfonamida kot novi fiziološko uporabni donorji nitroksila
US7696373B2 (en) 2006-04-13 2010-04-13 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
AU2008304200B2 (en) 2007-09-26 2013-12-19 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
JP5654450B2 (ja) 2008-05-07 2015-01-14 カルディオキシル ファーマシューティカルズ，インク． ニトロキシル供与体としての新規ニトロソ化合物およびその使用方法
US20110160200A1 (en) 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
CN102753520B (zh) 2009-12-07 2016-06-08 约翰斯霍普金斯大学 N-酰氧基磺酰胺和n-羟基-n-酰基磺酰胺衍生物
MX356796B (es) * 2009-12-07 2018-06-14 Cardioxyl Pharmaceuticals Inc Derivados de hidroxilamina bis-acilados.
JP6177246B2 (ja) 2011-10-17 2017-08-09 ザ・ジョンズ・ホプキンス・ユニバーシティ ヒドロキシルアミンで置換された、ｈｎｏ供与体としてのメルドラム酸、バルビツール酸、及びピラゾロンの誘導体
US10245249B2 (en) 2013-01-18 2019-04-02 Cardioxyl Pharmaceuticals, Inc. Pharmaceutical compositions comprising nitroxyl donors
US9682938B2 (en) 2014-05-27 2017-06-20 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
EP3148983A1 (en) 2014-05-27 2017-04-05 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors

Also Published As

Publication number Publication date
BR112014009282B1 (pt) 2021-12-14
US20140275134A1 (en) 2014-09-18
IL232101A (en) 2017-04-30
US9862699B2 (en) 2018-01-09
EP2776402B1 (en) 2017-07-26
KR102061537B1 (ko) 2020-01-03
IL232101A0 (en) 2014-05-28
CA2852914C (en) 2019-11-26
CA2852914A1 (en) 2013-04-25
MX2014004596A (es) 2014-09-04
BR112014009282A8 (pt) 2020-04-22
KR20140107197A (ko) 2014-09-04
AU2013201929B2 (en) 2015-07-23
CN104053647A (zh) 2014-09-17
SG11201401587QA (en) 2014-07-30
CN108409662B (zh) 2021-10-26
US9181213B2 (en) 2015-11-10
US9499511B2 (en) 2016-11-22
JP6177246B2 (ja) 2017-08-09
AU2013201929A1 (en) 2013-05-02
US20160115148A1 (en) 2016-04-28
AU2015246114A1 (en) 2015-11-12
EP2776402A1 (en) 2014-09-17
MX363306B (es) 2019-03-20
CN108409662A (zh) 2018-08-17
WO2013059194A1 (en) 2013-04-25
BR112014009282A2 (pt) 2017-06-13
CN104053647B (zh) 2018-06-01
US20170050947A1 (en) 2017-02-23
JP2015501308A (ja) 2015-01-15

Similar Documents

Publication Publication Date Title
HK1200168A1 (en) Meldrum s acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors hno
IL261372A (en) Preparations, uses and solid forms of obeticholic acid
HK1210778A1 (en) Pyrimidine pyrazolyl derivatives
HK1202774A1 (en) Isoxazoline derivatives used in the control of ectoparasites
EP2875024A4 (en) HIV TREATMENT WITH AMIDOSUBSTITUTED PYRIMIDINONE DERIVATIVES
IL250370A0 (en) Propionic acid derivatives substituted with heteroaroylamino in position 3 and their use as pharmaceuticals
HK1188215A1 (en) Diaminopyrimidine derivatives and processes for the preparation thereof
IL249826A0 (en) Propionic acid derivatives converted in 3-heteroylamino and their use in pharmaceutical preparations
EP2787002A4 (en) OLEANOIC ACID AMIDATE DERIVATIVES, METHOD OF MANUFACTURE AND ITS USE
HK1187335A1 (en) Amino-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals 3--
EP2766501A4 (en) NUCLEIC ACID AMPLIFICATION AND USE THEREOF
EP2913325A4 (en) SUBSTITUTED PYRIMIDINE COMPOUND AND APPLICATIONS THEREOF
IL248698A0 (en) History of 1-h-pyrrolidine-4,2-dione and processes for their preparation
EP2805956A4 (en) GAMBOGIC ACID DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF
EP3068400A4 (en) Methods for reducing uric acid levels using barbiturate derivatives
IL240447A (en) Propionic Acid-Baryl Acid Derivatives and Their Use as Pharmaceutical Preparations
IL240422B (en) Bi-aryl derivatives of propionic acid and their use as medicinal preparations
AU2011100053A4 (en) Online Depreciation System and associated formulae and Processes
GB201115851D0 (en) Thermally stable rivet
PT2584008E (pt) Corantes de ácidos trisazo à base de naftóis
AU2012901711A0 (en) Per-processor queues